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Excessive postoperative bleeding after heart operations continues to be a 
source of morbidity. This prospective double-blind study evaluated epsilon- 
aminocaproic acid as an agent to reduce postoperative bleeding and 
investigated its mode of action. One hundred three patients were randomly 
assigned to receive ither 30 gm epsilon-aminocaproic a id (51 patients) or 
an equivalent volume of placebo (52 patients). In a subset of these patients 
(14 epsilon-aminocaproic acid, 12 placebo), tests of platelet function and 
fibrinolysis were performed. Results: By multivariate analysis, three factors 
were associated with decreased blood loss in the first 24 hours after 
operation: epsilon-aminocaproic a id versus placebo (647 ml versus 839 ml, 
p = 0.004), surgeon 1 versus all other surgeons (582 ml versus 978 ml, p = 
0.002), and no intraaortic balloon versus intraaortic balloon pump use (664 
ml versus 1410 ml, p = 0.02). No significant differences in platelet function 
could be demonstrated between the two groups. Inhibited fibrinolysis, as 
reflected by less depression of the euglobulin clot lysis and no rise in 
D-dimer levels, was significant in the epsilon-aminocaproic acid group 
compared with the placebo group. Conclusion: The intraoperative use Of 
epsilon-aminocaProic a id reduces postoperative cardiac surgical bleeding. 
(J Thorac Cardiovasc Surg 1996;112:1098-107) 
B leeding after heart operations continues to be a concern for cardiac surgeons. Treatment during 
the operation with aprotinin reduces bleeding, but 
that drug is expensive and may cause such compli- 
cations as renal failure, coronary graft occlusion, 
myocardial infarction, and allergic reaction. TM 
Treatment of bleeding after heart operations with 
epsilon-aminocaproic acid (EACA) was reported in 
1967 by Sterns and Lillehei. 5 Several other authors 
have since confirmed EACA's effectiveness, but the 
drug appears to be regarded as secondary in impor- 
tance to aprotinin. 6-1° In our previous investigation 
of the use of low-dose EACA, we found that it 
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diminished bleeding after cardiac operations. 11We 
and others have since begun prophylactic use of the 
drug in larger doses. 1° This randomized, prospective 
double-blind study compared patients receiving 
high-dose EACA with a control group of patients 
receiving a placebo and investigated the mechanism 
of action of EACA during cardiopulmonary b pass 
(CPB). 
Material and methods 
After protocol approval by the Human Subjects Re- 
search Committee of the University of Massachusetts 
Medical Center, informed consent was obtained from 103 
patients. Consenting patients were then prospectively 
randomly assigned to receive EACA (Amicar; Lederle 
Laboratories, Pearl River, N.Y.; 51 patients) or a similar 
volume of 0.9% saline solution (52 patients ) in a double- 
blind study. Random assignment by means of a random 
number table and rug preparation were performed by 
the hospital pharmacy. Surgeons, perfusionists, anesthesi- 
ologists, and all laboratory personnel were unaware 
whether each patient received placebo r EACA. Patients 
in the treatment group received a total of 30 gm EACA: 
10 gm intravenously before skin incision. 10 gm intrave- 
nously after heparin administration, and 10 gm intrave- 
nously at the discontinuation of CPB but before prota- 
mine administration. Patients in the control arm group 
received saline solution in the same volumes and with the 
same timing. Heparin was administered per protocol at 
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400 U/kg, and incremental doses were given during the 
operation to maintain the activated clotting time at 
greater than 400 seconds. Protamine for heparin neutral- 
ization was administered per protocol at 1 mg/100 U total 
heparin dose. Patients requiring emergency operations, 
those with abnormal results of preoperative bleeding 
studies, and those who were pregnant were excluded from 
the study; no other exclusion criteria were used. Eligible 
patients included those needing coronaly bypass or valve 
operations. Closure time was defined as the time from 
termination of CPB to the application of the dressing. The 
dose of EACA was chosen on the basis of our previous 
study, ~1 in which a total of 11 gm EACA was adminis- 
tered, and on the larger 30 gm dose administered by Daily 
and colleagues. 1°Patient body surface areas in the study 
population ranged 1.40 to 2.78 m z (mean 1.96 m2). 
Postoperative chest tube drainage was not reinfused. The 
trigger for postoperative transfusion was a hematocrit 
lower than 25%. 
For all patients, routine preoperative and postoperative 
hematologic and coagulation studies performed consisted 
of complete blood cell count, prothrombin time, partial 
thromboplastin time, bleeding time, and thrombin time. 
Postoperative blood loss, as measured by chest tube 
drainage, and blood component therapy were recorded. In 
a subset of 26 patients (14 EACA, 12 control), various 
hemostatic tests were performed. These tests were of two 
types, those evaluating platelet function and those mea- 
suring fibrinolysis. These included fibrinogen level, anti- 
plasmin level, D-dimer level, euglobulin lysis time, anti- 
thrombin III level, and platelet count measured before 
operation, after heparin administration, 45 minutes after 
initiation of CPB, 5 minutes after protamine administra- 
tion, 2 hours after operation, and 24 hours after opera- 
tion. Bleeding time was measured before operation and 2 
hours after operation. These assays were all performed as 
described elsewhere. I2 After the Swan-Ganz catheter 
(Baxter Healthcare Corp., Edwards Div., Irvine, Calif.) 
had been placed, 5 ml blood was withdrawn from it before 
blood samples were drawn. 
In addition and at the same time intervals, whole blood 
flow cytometry (performed as described elsewhere 13) was 
used to measure the expression of platelet surface glyco- 
protein (GP) Ib, GPIIb-IIIa complex, fibrinogen binding 
to the GPIIb-IlIa complex, and P-selectin. The following 
monoclonal antibodies were used in these studies: S12 
(Centocor, Inc., Malvern, Pa.) is directed against P- 
selectin]4, 15 a component of the c~-granule membrane of 
resting platelets that is expressed on the platelet surface 
membrane only after platelet degranulation and secre- 
tion.14. 16 6D1 (provided by Barry S. Coller, Mount Sinai 
Medical Center, N.Y.) is directed against he von Wille- 
brand factor binding site on the amino terminal domain of 
platelet membrane GP Ibc~] 7' is Y2/51 (DAKO Corp., 
Carpenteria, CaliL) is directed against platelet membrane 
GPII Ia] 9 7E3 (also provided by Coller) is directed at the 
fibrinogen binding site on the GPIIb-IIIa complex. 2° F26 
(provided by Harvey Gralnick, National Institutes of 
Health Clinical Center, Bethesda, Md.) is directed against 
a conformational change in fibrinogen bound to the 
GPIIb-IIIa complex. 21'22 $12, 6D1, 7E3, and F26 were 
biotinylated as described elsewhere] 3'23 Fluorescein iso- 
Table I. Preoperative patient characteristics 
EACA Control 
(n : 51) (n = 52) p 
Male/female ratio 35/16 40/12 NS 
Age (yr) 64.7 + 12.! 64.2 _+ 12.4 NS 
Reoperation (no.) 5 (9.8%) 7 (13.5%) NS 
Hematocrit (preoperative) (%) 40.4 +_ 4.9 40.5 _+ 4.0 NS 
PT (preoperative) (sec) 13.0 ~ 0.98 13.1 _+ 0.93 NS 
PTT (preoperative) (sec) 43.3 _+ 18 43.9 _+ 22 NS 
BSA (m 2) 1.98 -+ 0.27 1.94_+ 0.24 NS 
Values are mean _+ standard deviation. NS, Not significant; PT, prothrom- 
bin time; PTZ partial t aromboplastin time; BSA, body surface area. 
thiocyanate-conjugated Y2/51 was purchased from 
DAKO. 
In a pilot study we compared preoperative blood ob- 
tained by peripheral venipuncture with preoperative 
blood obtained through the Swan-Ganz catheter and 
found no statistical difference in the binding of monoclo- 
nal antibodies S12, 6D1, 7E3, and F26 (n = 9). Drawing 
the blood through the Swan-Ganz catheter did not result 
in platelet activation or other platelet surface changes, so 
blood was obtained from the Swan-Ganz catheter in all 
subsequent s udies. 
Statistical methods. The primary outcome variable was 
blood loss through the chest tubes at 24 hours. Baseline 
characteristics and operative data for the control and 
EACA groups were compared by an unpaired t test for 
continuous variables and by X a tests for association of 
categoric variables. A multivariate analysis was used to 
adjust for confounding factors in the blood loss correla- 
tion and to determine the factors independently predictive 
of blood loss. Because of skewed (nonnormal) distribution 
of blood loss and large, unequal variances, the natural og 
of blood loss, rather than the actual blood loss, was used 
for the calculation of statistical significance. Differences 
were considered significant at a 95% confidence level (c~ 
= 0.05). 
Results 
Preoperative patient variables did not differ sig- 
nificantly between the EACA and control groups 
with respect o age, sex, reoperations, or preopera- 
tive clotting factors; all of which were normal in both 
groups (Table I). The following operative variables 
also did not differ significantly between the two 
groups: surgeon, cardioplegia temperature, opera- 
tion performed, and use of internal mammary grafts 
(Table II). CPB time, however, was significantly 
longer in the EACA group (148 minutes EACA vs 
129 minutes control, p = 0.02), as was crossclamp 
time (85 minutes EACA vs 73 minutes control, p = 
0.04). Mean closure time was 58 minutes in the 
EACA group and 54 minutes in the control group 
(p = 0.2) Closure time for surgeon 1 was 55 minutes; 
for the other surgeons it was 58 minutes (p = 0.3). 
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Fig. 1. Platelet surface expression of GPIb (von Wille- 
brand factor eceptor) did not change significantly during 
or after CPB, irrespective of whether patients received 
EACA (closed circles) or placebo (open circles). Platelet 
surface GPIb was determined atindicated time points by 
whole blood flow cytometry with monoclonal antibody 
6D1. PRE-OP, Preoperative; FIEPARIN, 5 minutes after 
initial heparin administration; 45 MIN CPB, 45 minutes 
into CPB; PROTAMINE, 5 minutes after protamine ad- 
ministration; 2 H POST, 2 hours after skin closure. Data 
are mean _+ standard error of the mean; n = 13 patients 
for EACA and n = 10 patients for placebo. Actual 
preoperative alues (mean flourescence _+standard error 
of the mean) were 33.8 _+ 2.4 in EACA group and 37.0 -+ 
1.8 in placebo group. 
In the subset of 26 patients who underwent more 
extensive hematologic testing, platelet surface GP 
expression and the fibrinolytic system were evalu- 
ated. By whole blood flow cytometry before, during, 
and after CPB, platelet surface expression of GPIb 
(yon Willebrand factor receptor) was found not to 
change significantly irrespective of whether the pa- 
tients received EACA (Fig. 1). Platelet surface 
expression of the GPIIb-IIIa complex (fibrinogen 
receptor) was also unchanged uring or after CPB 
irrespective of the use of EACA (Fig. 2). In addi- 
tion, we used monoclonal antibody F26 to measure 
directly the amount of fibrinogen bound to the 
platelet surface GPIIb-IIIa complex. Platelet activa- 
tion results in a conformational change in the 
GPIIb-IIIa complex that allows fibrinogen to bind to 
this complex. As a result of its binding to the 
GPIIb-IIIa complex, fibrinogen in turn changes con- 
formation. Only when fibrinogen is in this new 
Table II. Operative variables of EACA and control 
groups 
EA CA Control 
(n = 51) (n = 52) p 
Surgeon 1/ 27/24 (44%/57%) 34/18 (56%/43%) 0.2 
other surgeons 
CABG only 39 38 NS 
No. of grafts 3.80 _+ 0.76 3.63 _+ 0.88 NS 
(CABG only) 
No. of grafts 3.63 + 0.97 3.54 _+ 0.92 NS 
(all CABG) 
ITA graft 30 29 NS 
VaNe 10 12 NS 
Valve per CABG 4 4 NS 
CPB time 148 -- 41 129 + 42 0.02 
Crossclamp time 85 + 28 73 + 29 0.04 
IABP 5 6 NS 
Pericardium closed 8 15 NS 
Reoperation 5 7 NS 
Values are mean _+ standard eviation. CABG, Coronary artery bypass 
grafting; NS, not significant; IABP, intraaortic balloon pump. 
conformation does monoclonal antibody F26 bind 
to fibrinogen. TM22 F26 binds only to activated, not 
resting, platelets. 2< 22 Fig. 3 demonstrates the effects 
of the combination of 20 mmol/L adenosine diphos- 
phate (ADP) with 20 mmol/L epinephrine on the 
platelet surface binding of monoclonal antibody 
F26, as determined by whole blood flow cytometry. 
In the absence of ADP and epinephrine, there was 
little binding of F26 and therefore little platelet 
activation. This finding demonstrates that CPB did 
not result in circulating activated platelets, regard- 
less of whether the patient received EACA. After 
the ex vivo addition of ADP and epinephrine, there 
was a marked increase in the platelet surface bind- 
ing of F26. This finding demonstrates that the 
reactivity of platelets (as determined by their ability 
to bind fibrinogen in response to ADP and epineph- 
rine) was unaffected by CPB and was not signifi- 
cantly affected by whether the patient received 
EACA. Finally, the platelet surface expression of 
P-selectin was minimal irrespective of whether 
EACA was used (Fig. 4). 
In evaluation of the fibrinolytic system, euglobulin 
clot lysis time was significantly ess depressed in the 
EACA group than in the control group (Fig. 5). 
Further evidence of fibrinolytic inhibition by EACA 
was obtained from the obliteration of  the CPB- 
associated increased in circulating plasma D-dimer 
in the EACA group (Fig. 6). Plasma fibrinogen fell 
in both groups, with no difference between the two 
groups (Fig. 7). Plasma antiplasmin and antithrom- 
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Fig. 2. Platelet surface xpression of the GPIIb-IIIa com- 
plex (fibrinogen receptor) did not change significantly 
during or after CPB, irrespective of whether patients 
received EACA (closed circles) or placebo (open circles). 
Platelet surface GPIIb-IIIa complex was determined at 
indicated time points (see Fig. 1) by whole blood flow 
cytometry with monoclonal antibody 7E3. Data are 
mean --- standard error of the mean; n = 13 patients for 
EACA and n = 9 patients for placebo. Actual preopera- 
tive values (mean flourescence -+ standard error of the 
mean) were 24.2 + 1.5 in EACA group and 20.2 + 0.9 in 
placebo group. 
bin I I I  fell to a similar degree in both groups (Figs. 
8 and 9). In these same 26 patients, the platelet 
count fell during the operation and then rose after 
operation, with no difference between EACA and 
placebo groups (data not shown). The preoperative 
bleeding times were 4.3 _+ 0.74 minutes in the 
EACA group and 4.5 +_ 0.26 minutes in the control 
group (p not significant; postoperative bleeding 
times were 5.3 ± 0.4 minutes in the EACA group 
and 7.2 _+ 1.3 minutes in the control group (p not 
significant). Within each group, the rise in bleeding 
time from preoperative to postoperative measure- 
ments was statistically significant (p = 0.02 in both 
EACA and control groups). 
Postoperative bleeding was decreased in the 
EACA group (Table III). At 12 hours, blood re- 
trieved from the chest tubes was 425 ml in the 
EACA group and 565 ml in the control group (p < 
0.004). At 24 hours, blood retrieved from the chest 
tubes was 647 ml in the EACA group and 839 ml in 
the control group (p = 0.002). No significant differ- 
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Fig. 3. Irrespective of whether patients received EACA 
(closed symbols) or placebo (open symbols), platelets cir- 
culated during and after CPB with little bound fibrinogen 
(circles), and platelets were normally reactive to combina- 
tion of ADP and epinephrine (ADP/epi), as determined by 
ability to bind fibrinogen to GPIIb-IIIa complex (squares). 
Fibrinogen binding to platelet surface GPIIb-IIIa complex 
was determined at indicated time points (see Fig. 1) by 
whole blood flow cytometry with monoclonal antibody 
F26. F26 binding to preoperative samples incubated with 
20 mmol/L ADP and 20 mmol/L epinephrine was defined 
as 100%. Data are mean + standard error of the mean; 
n = 12 patients for EACA and n = 7 patients for placebo. 
Preoperative fibrinogen binding to platelet surface GPIIb- 
IIIa complex in absence of agonist (mean flourescence _+ 
standard error of the mean) was 5.8 + 2.3 in EACA 
group, and 4.5 + 1.3 in placebo group. Binding with 
ADP/epi agonist was 39.7 -+ 8.3 in EACA group and 
58.5 -+ 13.9 in placebo group. 
ence, however, was observed in the number of 
packed red blood cells administered to the two 
groups during the first 24 hours (0.94 units in the 
EACA group and 1.12 units in the control group). 
Neither did any significant difference exist with 
respect o other blood products (cryoprecipate and 
fresh-frozen plasma) administered to the two 
groups. Postoperative hematocrit at discharge and 
immediate postoperative clotting studies were also 
similar in the two groups (Table III). 
By multivariate analysis, three factors were found 
to correlate with postoperative blood loss at 24 
hours (Table IV). In addition to the use of EACA, 
surgeon 1 was associated with less bleeding than the 
other surgeons taken in aggregate (582 vs 978 ml, 
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Fig. 4. Platelet surface expression of P-selectin (reflect- 
ing granule secretion) was minimal whether patients re- 
ceived EACA (closed circles) or placebo (open circles). 
Platelet surface P-selectin was determined at indicated 
time points (see Fig. 1) by whole blood flow cytometry 
with monoclonal antibody $12. $12 binding to preopera- 
tive samples incubated with 2 U/ml thrombin was defined 
as 100%. Data are mean _+ standard error of the mean; 
n = 12 patients for EACA and n = 9 patients for placebo. 
Preoperative alues (mean flourescence -+standard error 
of the mean) were 2.7 +- 0.4 in EACA group and 2.6 -+ 1.8 
in placebo group. 
p = 0.002). Patients with intraaortic balloon pump 
(IABP) use had increased blood loss compared with 
patients not requiring an IABP (1410 vs 664 ml, p = 
0.02). Despite the fact that a disproportionate num- 
ber of the patients in the control group were per- 
formed by the surgeon with the lowest bleeding rate, 
the EACA group had less bleeding. Although CPB 
time and crossclamp time were longer in the EACA 
group by univariate analysis, by multivariate analy- 
sis, these factors were not found to be associated 
with postoperative bleeding. 
Although the blood transfusion requirement did 
not differ significantly between the EACA and con- 
trol groups, two other variables did affect blood use 
during the first 24 hours (Table V). Men received a
mean of 0.78 units of packed red cells compared 
with women, who received 1.68 units (p = 0.0001). 
When normalized for body surface area, the packed 
red cells were 0.41 per patient/m 2 for men and 0.98 
per patient/m 2 for women. Patients undergoing pri- 
mary operation received 0.84 units, compared with 
2.42 units for patients undergoing reoperation (p = 
140 
W 
1-- 
03 
U3 ) -  
J c 
o-  E 
Z v  
.d  
m 
0 
..J 
(.9 
W 
120 
100 
80 
60 
40 
20 
0 
• EACA 
0 Placebo 
i i i i t 
[3_ Z 12121 W b--  [ - -  
o ~ n z m o~ 
-- 0 0 
I < 0 ~ O_ a_ 
W n < 
o~ w z ~_ I z: 
n "I- ~ 0 
u3 O- C~ 
Fig. 5. Euglobulin clot lysis time, assay of fibrinolytic 
activity, was significantly longer, indicating less fibrinolysis 
in patients receiving EACA (closed circles) than in control 
patients (open circles). Time points as given in Fig. 1. Data 
are mean _+ standard error of the mean; n = 14 patients 
for EACA and n = 11 patients for placebo. 
0.005). To assess the possibility that smaller preop- 
erative red cell mass in the women led to a greater 
proportion of red cell mass lost and therefore a 
greater transfusion requirement, a metric was con- 
structed that measured the relative proportion of the 
red cell mass lost. This metric was calculated by 
dividing the 24 hour blood loss by the product of the 
preoperative hematocrit and body weight. This rel- 
ative measure was 0.24 in men and 0.25 in women. 
The difference in red cell transfusions between men 
and women cannot be explained by a difference in 
the proportion of the preoperative r d cell mass lost. 
Similarly, patients requiring an IABP received 
2.64 units of packed red cells, compared with 0.83 
units for those not requiring an IABP (p = 0.008). 
One patient died in the EACA group and none died 
in the placebo group. The single death was that of a 
71-year-old woman 3 days after reoperative coro- 
nary artery bypass grafting when free rupture of the 
posterior left ventricle occurred as a result of a 
perioperative myocardial infarction. All coronary 
grafts were patient at autopsy. 
Other than the decreased bleeding in the EACA 
group, no differences in complications were ob- 
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Fig. 6. Administration ofEACA inhibited fibrinolysis, as 
evidenced by obliteration of CPB-associated increase in 
circulating plasma D-dimer. Time points as given in Fig. 1. 
Data are mean -+ standard error of the mean; n = 14 
patients for EACA and n = 10 patients for placebo. 
served between control and EACA groups. Al- 
though a trend toward higher increased prevalence 
of electrocardiographically diagnosed myocardial 
infarction (new Q waves or loss of R waves) in the 
EACA group than in the control group (5 of 51 vs 2 
of 52;p = 0.08) was observed, this difference was not 
statistically significant. Furthermore, no differences 
in postoperative creatine kinase level or creatine 
kinase index were seen between the two groups. No 
cerebrovascular ccidents occurred in the EACA 
group; two occurred in the control group (p = 0.33). 
One patient in the EACA group and three in the 
control group required reexploration for postoper- 
ative bleeding (p = 0.6). 
Discussion 
Multiple factors contribute to the bleeding dia- 
thesis seen after cardiac operations performed with 
CPB. Not all are understood, and there is disagree- 
ment regarding their relative importance. The two 
major hematologic abnormalities leading to in- 
creased postoperative hemorrhage are decreased 
platelet function and increased fibrinolysis. 24-26 
Bleeding time increases during and after CPB. This 
was long considered to reflect an intrinsic platelet 
defect caused by the nonphysiologic nature of CPB, 
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Fig. 7. Plasma fibrinogen levels decreased uring CPB, 
irrespective of whether patients received EACA (closed 
circles) or placebo (open circles). Time points as given in 
Fig. 1. Data are mean _+ standard error of the mean; n = 
14 patients for EACA and n = 12 patients for placebo. 
Actual preoperative values (+ standard error of the 
mean) were 405.3 _+ 33.9 mg/dl (EACA) and 313.8 + 36.6 
mg/dl (placebo). 
but Kestin and associates 27have proposed that the 
platelet defect occurs because of an antagonistic 
external force, such as cold, or lack of availability of 
platelet agonists. Previous studies that used whole 
blood flow cytometry failed to show any loss of 
platelet membrane receptors, 27but studies of plate- 
let-rich plasma or washed platelets do show such 
alterations.2a, 29 This difference is likely to be the 
result of artifactual in vitro changes in platelet 
membrane receptors caused by the separation pro- 
cedures required for the preparation of platelet-rich 
plasma and washed platelets. 
The mechanism of the fibrinolysis is more clearly 
understood.24, 263o Blood coming into contact with 
foreign surfaces in the CPB circuit initiates the 
contact phase of coagulation and generates kal- 
likrein. This in turn stimulates bradykinin release, 
and both molecules activate tissue plasminogen 
activator, which converts plasminogen to plasmin, a 
potent fibrinolytic and fibrinogenolytic agent. Hep- 
arin also directly increases plasmin activity. Further 
consequences of CPB are a reduction in circulating 
~2-antiplasmin a d an increase in circulating plas- 
minogen activator inhibitor- i)  1
Aprotinin has been shown by numerous tudies to 
reduce bleeding after cardiac operations, l'a'3a It 
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Fig. 8. Plasma antiplasmin levels decreased during CPB, 
irrespective of whether patients received EACA (closed 
circles) or (open circles). Time points as given in Fig. 1. 
Data are mean _+ standard error of the mean; n = 14 
patients for EACA and n = 12 patients for placebo. 
Actual preoperative alues (percentage of mean values in 
normal volunteers -- standard error of the mean) were 
92.3% _+ 4.5% (EACA) and 85.0% + 2.5% (placebo). 
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Fig. 9. Plasma antithrombin III levels decreased uring 
CPB, irrespective of whether patients received EACA 
(closed circles) or placebo (open circles). Time points as given 
in Fig. 1. Data are mean _+ standard error of the mean; n = 
10 Patients for EACA and n = 7 patients for placebo. Actual 
preoperative alues (percentage of mean values in normal 
volunteers +_ standard error of the mean) were 94.2% _+ 
7.1% (EACA) and 85.1% + 3.3% (placebo). 
Table III. Postoperative blood loss, transfusions, 
coagulation values, hematocrit, and reexploration in 
the EACA and control groups 
EACA Control p 
Blood loss, 12 hr (ml) 425 -+ 412 565 + 488 0.004 
Blood loss, 24 hr 647 ± 488 ml 839 _+ 634 ml 0.002 
Units RBC, 24 hr 1.13 +_ 1.37 1.35 +- 2.02 NS 
Units FFP, 24 hr 0.2 _+ 0.8 0.38 -+ 1.24 NS 
Hematocrit at discharge 29.9 -+ 3.6 29.8 ± 3.2 NS 
(%) 
PT (postoperative) (sec) 14.1 ± 1.0 14.0 _+ 1.3 NS 
PTT (postoperative) 34.5 ± 6.2 35.0 _+ 9.2 NS 
(sec) 
TT (postoperative) (sec) 19.0 -+ 5.4 17.4 ± 8.5 NS 
Reexploration (bleeding) 1 3 NS 
Values are mean _+ standard eviation. RBC, Red blood cells; NS, not 
significant; FFP, fresh-frozen plasma; PT, prothrombin time; PTT, partial 
thromboplastin me; TT, thrombin time. 
interrupts everal steps in the cascade of hemato- 
logic changes during CPB that lead to the bleeding 
diathesis.26, 33-38 These salutary effects occur at least 
in part as a result of aprotinin's direct antiplasmin 
activity, its inhibition of kallikrein, its inhibition of 
urokinase, and its preservation of normal levels of 
a2-antiplasmin. Aprotinin has also been reported to 
preserve platelet function, 1'29 although other re- 
ports suggest hat its role in platelet preservation is 
absent or minimal compared with its interruption of 
fibrinolysis. 39'4° Although it is of unquestioned 
value in reducing blood loss, aprotinin is expensive. 
Questions have also been raised about its safety. 
Suggestions that aprotinin causes abnormal intra- 
vascular clotting, leading to organ dysfunction, have 
been made by several investigators. 2-4 For these two 
reasons we investigated the ability of EACA to 
reduce postoperative bleeding and also the mecha- 
nism of its action. EACA exerts its antifibrinolytic 
effect by binding with plasminogen and plasmin, 
displacing them from fibrin. 24 It also inhibits tissue 
plasminogen activator activity. 6 Because plasmin 
reduces the platelet GPIb receptors 41 and thus 
reduces platelet adhesion, and because the fibrin 
degradation products of fibrinolysis also inhibit 
platelet function, we measured the effect of EACA 
on platelet function in 26 patients by means of 
detailed hematologic testing. 
In this study, the platelet surface expressions of 
P-selectin, GPIb, the GPIIb-IIIa complex, and fi- 
brinogen binding to platelet surface GPIIb-IIIa 
were all unaffected by the administration of EACA 
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Table IV. Multivariate analysis." Effect of operative 
and patient variables on blood loss 
Variable Blood loss at 24 hr (ml) p 
Surgeon 1 582 _+ 262 0.003 
Other surgeons 978 ± 786 
EACA 647 ± 488 0.002 
Control 839 ± 634 
IABP 1410 ± 1089 0.02 
No IABP 664 ± 419 
Pericardium closed 562 _+ 280 0.2 
Pericardium left open 796 ± 622 
Male 792 ± 575 0.2 
Female 615 _+ 551 
Blood loss adjusted for BSA 
Male 400 _+ 310 0.5 
Female 354 + 329 
Reoperation 972 ± 738 0.1 
Primary operation 714 ± 544 
Multivariate analysis. Values are mean + standard deviation. IABP, 
lntraaortic balloon pump; BSA, body surface area. 
to patients during CPB. Each of these antigens i of 
functional importance. P-selectin, an a-granule 
membrane protein that is expressed on the platelet 
surface only after degranulation, ~4'16 mediates ad- 
hesion of activated platelets to neutrophils and 
monocytes. 42'43 GPIb, a receptor for yon Wille- 
brand factor, is critical for platelet adhesion to 
damaged blood vessel walls. 44 The GPIIb-IIIa com- 
plex, a receptor for fibrinogen, yon Willebrand 
factor, and fibronectin, is critical for platelet aggre- 
gation. 45 The lack of any effect of EACA on P- 
selectin, GPIb, the GPIIb-IIIa complex, and fibrin- 
ogen binding to the GPIIb-IIIa complex strongly 
suggests that the EACA-dependent decrease in 
CPB-associated blood loss is not mediated through 
a platelet-dependent mechanism. 
We examined the fibrinolytic system in the same 
subset of th e study population. In the control group, 
evidence of increased fibrinolysis was seen. This has 
been previously reported uring CPB. 26 We found a 
marked increase in plasma D-dimer concentrations 
and a corresponding drop in euglobulin lysis time in 
the control group; in the EACA group no change 
occurred in D-dimer concentrations, and although 
the euglobulin clot lysis time fell slightly, it did so to 
a lesser extent han in the control group. 
The major end point of the study was postopera- 
tive bleeding. At both 12 hours and 24 hours after 
operation, univariate and multivariate analyses 
demonstrated a significant reduction in blood loss in 
the EACA group. This is consistent with our previ- 
ous study and several other studies, which showed 
Table V. Multivariate analysis." Effect of operative 
and patient variables on blood transfusions given 
Variable Blood given (units~24 hr) * p 
Male 0.78 _+ 1.40 0.0001 
Female 1.68 +_ 1.25 
Primary operation 0.84 ± 1.17 0.005 
Reoperation 2.42 _+ 2.19 
No IABP 0.83 _+ 1.10 0.008 
IABP 2.64 ± 2.42 
EACA 0.94 ± 1.21 0.3 
Control 1.12 ± 1.58 
Surgeon 1 0.87 _+ 1.16 0.5 
Other surgeons 1.28 + 1.71 
Multivariate analysis. Values are mean -+ 
lntraaortic balloon pump. 
*Packed red blood cell units. 
standard deviation. IABP, 
reduced bleeding as a result of EACA use. 6' v, 9-~1 
We assessed bleeding by directly measuring chest 
tube effluent. When these measurements were nor- 
malized for body surface area, the conclusions did 
not change. 
In our previous tudy of EACA, 11 we limited the 
patient population to those patients undergoing 
elective coronary artery bypass operations, as did 
Daily and colleagues t° in their recent publication. 
Because the difference in bleeding at t2 hours 
between the control (332 ml) and EACA (272 ml) 
groups in our earlier study was statistically signifi- 
cant but clinically insubstantial, we broadened the 
inclusion group in the current study. All patients 
undergoing coronary bypass operations, vane oper- 
ations, or a combination of the two were included. 
Pregnant women, patients with known bleeding 
disorders, and patients requiring emergency opera, 
tion were excluded. 
Bleeding after heart operations i a problem of 
such magnitude that it is curious that little recogni- 
tion or importance seems to have been given to 
reports demonstrating the efficacy of EACA pub- 
lished during the infancy of cardiac surgery. In 1967, 
Sterns and Lillehei 5 almost halved postoperative 
bleeding by giving EACA at the conclusion of CPB. 
In 1976, Lambert and colleagues 8 showed prompt 
resolution of established postoperative bleeding af- 
ter EACA treatment. The interest in aprotinin 
therapy may have rekindled interest in EACA. 
This rekindled interest assumes greater signifi- 
cance as a result of the current focus on medical 
costs. Purchased through our hospital pharmacy, the 
commonly used high-dose aprotinin regimen (20 × 
106 kIU before bypass, 20 × 106 kIU in heart-lung 
1 10 6 Vander Salm et aL 
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pump, and 5 × 106 kIU/hr after 1 hour for the 
duration of the operation) costs our hospital $150 
pe r 10 × 106 kIU, or about $785 per patient. A 30 
gm dosage Of EACA (the total dose used in this 
study) costs our hospital $6.96--a difference be- 
tween the two drugs of about $778 per patient. This 
cost differential p laces aprotini n at a considerable 
disadvantage in the choice between the two drugs on 
the basis of a cost-benefit analysis. 
As in our previous investigation of EACA, 1~ we 
found no morbidity associated with the drug. Other 
studies have also shown no increase in complications 
from EACA use. v' 9, 10 Because of the statistically 
insignificant increase in perioperative myocardial 
infarctions in the treatment group, however, this 
question must still be considered unanswered. With 
only 103 enrolled patients, it is possible that the 
study lacked sufficient statistical power to detect 
other differences in complication rates between the 
two groups. 
Increased attention to control of bleeding in the 
terminal stages of the operation may be one cause of 
decreased postoperative bleeding. Although such 
increased attention cannot be measured irectly, the 
operative time spent after the patient has been 
weaned from CPB and all the cardiac portions of the 
operation have been completed could be used as a 
surrogate measure. There was no difference in clo- 
sure time (termination of CPB to dressing applica- 
tion) between the EACA and control groups. An 
unexpected and unexplained finding in this study 
was that the patients Of one surgeon (surgeon 1) had 
significantly less bleeding than did those of the other 
surgeons. We have since discovered that this result 
parallels that in our total patient database xtending 
back several years. In this study, the closure time for 
surgeon 1 was slightly but not significantly less than 
for the aggregate of the other surgeons. We there- 
fore could not conclude that extra time (or care) in 
closing contributed to the difference in bleeding. 
We conclude that EACA reduces postoperative 
bleeding after heart operations at far less expense 
than aprotinin and with no detectable morbidity. 
The EACA-dependent decrease in the CPB:associ- 
ated blood loss is mediated by inhibition of the 
fibrinolytic system, not by a plateiet-dependent 
mechanism. 
We thank Drs. Barry S. Coller and Harvey Gralnick for 
generously providing monoclonal antibodies, Drs. Anne 
M. Stoddard and Frederick A. Anderson, Jr., for perform- 
ing the statistical evaluation, and Marc Barnard, MS, and 
Hollace MacGregor, BS, for performing the hematologic 
and fibrinolytic analyses. 
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